Summit Therapeutics Partners with Pfizer to Assess Ivonescimab in Combination with Pfizer’s ADCs for Various Solid Tumor Settings
Shots:
- Summit has entered into a clinical trial collaboration with Pfizer to assess safety & anti-tumor activity of ivonescimab with multiple Pfizer’s vedotin ADCs in solid tumors; trials are expected to initiate in mid-2025
- As per the deal, Summit will supply ivonescimab for proposed trials & Pfizer will handle operations, with both firms jointly overseeing the trials. Each party retains rights to their respective products
- Ivonescimab (bsAb) is being evaluated in 3 P-III trials: HARMONi (with CT vs PBO + CT) for EGFRm LA/M non-sq. NSCLC with topline data expected in mid-2025, HARMONi-3 (with CT vs Keytruda + CT) for 1L metastatic NSCLC & HARMONi-7 (vs Keytruda) for 1L, PD-L1+ metastatic NSCLC
Ref: Bussinesswire | Image: Pfizer & Summit Pharmaceuticals
Related News:- Pfizer Reports Data from P-III (TALAPRO-2) Trial of Talzenna + Xtandi for Metastatic Castration Resistant Prostate Cancer (mCRPC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
